BioCryst announces approval of Orladeyo (berotralstat) by the National Administration of Drugs, Foods and Medical Devices (ANMAT) in Argentina Biocryst Pharmaceuticals Inc. today announced that the National Administration of Drugs, Foods, and Medical Devices [...]
BioCryst Launches Orladeyo (berotralstat) in Spain Biocryst Pharmaceuticals Inc today announced that the Spanish Ministry for Health (Ministerio de Sanidad) has granted marketing authorization for oral, once-daily Orladeyo (berotralstat) for the routine prevention of [...]
European Commission approves label update for lanadelumab, for a broader group of pediatric patients with recurrent attacks of hereditary angioedema (HAE) Takeda today announced the European Commission has approved Takhzyro (lanadelumab) for the routine [...]
Intellia Therapeutics receives European Union orphan drug designation for NTLA-2002, an investigational in-vivo CRISPR genome editing treatment for Hereditary Angioedema Intellia Therapeutics today announced that the European Commission (EC) has granted orphan drug designation [...]
KalVista Pharmaceuticals presents real-world data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology KalVista Pharmaceuticals presented real-world data on anxiety associated with the use of injectable on-demand [...]
Orchard Therapeutics reports third quarter 2023 financial results and highlights recent business accomplishments Orchard Therapeutics announced several business accomplishments along with its financial results for the quarter ended 30 September 2023. Bobby Gaspar MD [...]
Astria Therapeutics reports third quarter financial results and provides a corporate update Astra Therapeutics reported financial results for the third quarter ended 30 September 2023 and provided a corporate update. Jill C. Milne, PhD, [...]
Kalvista Pharmaceuticals announces Phase-3 KONFIDENT trial milestone achieved KalVista Pharmaceuticals provided clinical trial and regulatory updates for its lead program sebetralstat, in development as a potential oral on-demand therapy for hereditary angioedema (HAE). Clinical [...]
Please join us in welcoming yet another member country to the global HAE family: HAE Mozambique as member country no. 98. The national contact is Daniella Nhaguilunguana. >> Read more about HAE Mozambique on the [...]
From Director Fiona Wardman, HAE Australasia HAE Australasia has a new CEO! Lisa Foster is an inclusive and authentic leader with extensive experience across Health, Disability, Mental Health, and Community Support Sectors. Lisa was [...]
The US HAEA is committed to delivering engaging and informative programs, services, and activities to our expansive membership of over 8,000 individuals. These initiatives aim to unite the HAE community in pursuit of our [...]
From Mihaela Sogoric, HAE Croatia The Association of Patients with Hereditary Angioedema HAE Croatia successfully organized the 3rd meeting of parents and children suffering from HAE with pediatricians in Tuheljske toplice. The pediatricians chose [...]
From Angela Metcalfe, CEO and Rachel Annals, EO, HAE UK: In the last few months, we have had lots of meetings with healthcare professionals and our pharmaceutical company representatives. We have also just returned [...]
From Ernst Greber, HAE Switzerland HAE Film: ‘HAE - Simply Explained’ with added French and Italian subtitles: The Swiss HAE Association has had a film produced in which the rare disease Hereditary Angioedema (HAE) [...]
From Michelle Cooper, President, Jacquie Badiou, Past President, and Daphne Dumbrille, COO, HAE Canada A few years ago, HAE Canada’s Past President, Jacquie Badiou, realized that HAEC would benefit from gaining accreditation from Imagine [...]
From Carla M. Goachet Boulanger, President, HAE Peru One of the goals of the 2023 proposed by the Board of Directors of HAE PERU was to encourage, motivate, and support the participation of youngsters [...]
From Maria (Marijk) Beekman-Kortekaas, President HAE the Netherlands We’re back! For years, HAE the Netherlands has not been very active. A year ago, a new board took over, and we started to rebuild the organization. [...]
From Jovana Cvetković Lazić, President, HAE Serbia Empowering HAE Advocacy: ‘Doctors in Purple’ Project Shines Light on Early Diagnosis In collaboration with esteemed medical professionals, HAE Serbia has recently unveiled the impactful ‘Doctors in [...]
From Parichehr Bahrain, HAE Iran HAE International Day (16 May 2023) in Immunology, Asthma and Allergy Research Institute, (IAARI) Tehran University of Medical Sciences, Iran On the Hereditary Angioedema (HAE) International Day, IAARI organized a [...]
From HAE Junior HAE juniors’ families joined the fourth educational summer camp. The fourth edition of the HAE Junior’s summer camp is successfully over! Let’s take a look back at the four days we spent [...]
Phew, it has been a whirlwind of activity in the Youngsters’ Community. We’ve just waved goodbye to our friends with the conclusion of the 2023 HAEi Regional Conference EMEA. With 60 young people with [...]
We are all familiar with the enriching conversations, valuable educational content, and unforgettable memories that unfold when a significant gathering of HAE community members takes place, and the 2023 US HAEA National Summit was [...]
Update from HAEi’s Executive Vice President Global Operations and Chief Compliance Officer, Jørn Schultz-Boysen Great to see so many people at the 2023 HAEi Regional Conference EMEA! For the past year (and longer), preparations [...]
Update from HAEi’s Executive Vice President Global Advocacy and Chief Diversity Officer, Fiona Wardman Advocacy is an essential tool to drive change. In my new role as Executive Vice President of Global Advocacy and [...]
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.